axatilimab

Contraindicated in:

OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Rep: Women of reproductive potential;
Pedi: Children <40 kg (safety and effectiveness not established).

Adv. Reactions/Side Effects ⬆ ⬇

CV: edema, hypertension

Derm: rash, pruritus

EENT: periorbital edema

F and E: hypercalcemia, hypophosphatemia

GI: ↑amylase, ↑lipase, ↑liver enzymes, diarrhea, nausea

Hemat: anemia, bleeding

Metab: ↓appetite

MS: ↑CK, pain

Neuro: dizziness, fatigue, headache

Resp: cough, dyspnea

Misc: fever, infection, infusion-related reactions

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Solution for injection: 50 mg/mL

Route/Dosage ⬆ ⬇

IV (Adults and Children ≥40 kg): 0.3 mg/kg (max dose = 35 mg) every 2 wk; continue until disease progression or unacceptable toxicity.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits colony stimulating factor-1 receptors, which reduces concentrations of monocytes and macrophages, thereby decreasing fibrosis and inflammation within tissues.

Therapeutic effects:

Reduced severity of chronic graft-versus-host disease.

Classifications ⬆ ⬇

Therapeutic Classification: none assigned

Pharmacologic Classification: monoclonal antibodies, temporary class

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Minimally distributed to tissues.

Metabolism/Excretion: Metabolized by catabolic pathways into small peptides.

Half-Life: 10.7–108 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	end of infusion	unknown

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other medications.
Advise patient of the signs/symptoms of infusion-related reactions and to seek medical assistance if any occur.
Rep: Advise women of reproductive potential to notify health care professional if pregnancy is planned or suspected. Advise women of reproductive potential to use effective contraception during therapy and for 30 days after last dose. Advise women not to breastfeed during therapy and for 30 days after the last dose.

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇